Rockefeller Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Rockefeller Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$286K	Buy	72,666 +1,000	+1%	+$3.64K	﹤0.01%	2407
2026 Q1	$221K	Hold	71,666	–	–	﹤0.01%	2439
2025 Q4	$108K	Buy	71,666 +35,000	+95%	+$83.2K	﹤0.01%	2683
2025 Q3	$95K	Buy	+36,666	New	+$107K	﹤0.01%	2599
2023 Q1	–	Sell	-1,666	Closed	-$3K	–	2521
2022 Q4	$3K	Hold	1,666	–	–	﹤0.01%	3453
2022 Q3	$4K	Hold	1,666	–	–	﹤0.01%	3391
2022 Q2	$4K	Hold	1,666	–	–	﹤0.01%	3535
2022 Q1	$6K	Hold	1,666	–	–	﹤0.01%	3270
2021 Q4	$7K	Hold	1,666	–	–	﹤0.01%	3135
2021 Q3	$10K	Hold	1,666	–	–	﹤0.01%	2885
2021 Q2	$13K	Hold	1,666	–	–	﹤0.01%	2662
2021 Q1	$17K	Hold	1,666	–	–	﹤0.01%	2345
2020 Q4	$25K	Sell	1,666 -1	-0.1%	-$19	﹤0.01%	1912
2020 Q3	$28K	Hold	1,667	–	–	﹤0.01%	1675
2020 Q2	$14K	Hold	1,667	–	–	﹤0.01%	1785
2020 Q1	$12K	Buy	+1,667	New	+$15.9K	﹤0.01%	1678

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Rockefeller Capital Management's ELDN Position: Q2 2026 in Review

Rockefeller Capital Management increased its Eledon Pharmaceuticals (ELDN) stake by 1.4% in Q2 2026, buying an estimated $3.64K and bringing the position to 72,666 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #2407.

Rockefeller Capital Management first reported a position in ELDN in Q1 2020 and has held it in 16 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Rockefeller Capital Management held 72,666 shares of Eledon Pharmaceuticals worth $286K as of Q2 2026.
Rockefeller Capital Management bought 1,000 Eledon Pharmaceuticals shares in Q2 2026, an estimated $3.64K.
Eledon Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2407 holding.
Rockefeller Capital Management first reported a position in Eledon Pharmaceuticals in Q1 2020 and has held it in 16 quarters since.
161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.